Regeneron agrees to $270m extension to supply Ebola medicine in US
Regeneron Pharmaceuticals has agreed to a $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government through 2031.
Regeneron Pharmaceuticals has agreed to a $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government through 2031.